<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products.” data-reactid=”19″>SIRION Biotech GmbH announced today that Beam Therapeutics licensed rights to use SIRION Biotech’s LentiBOOST™ for use in their CAR-T cell products.

CAR-T cell therapy represents a promising and future-defining shift in cancer treatment. Beam Therapeutics is developing a new generation of CAR-T product candidates using its proprietary base editing technology.

Under the terms of this agreement, SIRION agreed to provide Beam with non-exclusive access to its proprietary lentiviral transduction enhancer LentiBOOST™ for clinical development and commercialization of Beam’s portfolio of CAR-T programs. SIRION will be entitled to undisclosed upfront and milestone payments and is eligible to receive royalties on future product net sales plus license fees tied to commercial success.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Dr. Christian Thirion, CEO and founder of SIRION Biotech GmbH explains: "LentiBOOST™ was engineered to improve lentiviral transduction of difficult cell types like T-cells and hematopoietic stem cells. This technology enables robust upscaling of the T-cell production process, and helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product while at the same time improving clinical efficacy by increasing vector copy numbers (VCN) per cell. We are delighted that the LentiBOOST™ technology may help Beam further enhance the clinical success of its CAR-T pipeline."” data-reactid=”22″>Dr. Christian Thirion, CEO and founder of SIRION Biotech GmbH explains: “LentiBOOST™ was engineered to improve lentiviral transduction of difficult cell types like T-cells and hematopoietic stem cells. This technology enables robust upscaling of the T-cell production process, and helps to reduce manufacturing costs by lowering the amount of lentiviral vectors needed for production of the cell product while at the same time improving clinical efficacy by increasing vector copy numbers (VCN) per cell. We are delighted that the LentiBOOST™ technology may help Beam further enhance the clinical success of its CAR-T pipeline.”

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content=""LentiBOOST™ is used in an increasing number of clinical trials in the US and in Europe and the technology is more and more considered as a gold standard in manufacturing of cell products. Our non-exclusive licensing strategy makes our technology available to a wide range of companies and research hospitals to boost the efficiency of their various clinical programs," says SVP of Business Development &amp; Licensing, Dr. Sabine Ott.” data-reactid=”23″>”LentiBOOST™ is used in an increasing number of clinical trials in the US and in Europe and the technology is more and more considered as a gold standard in manufacturing of cell products. Our non-exclusive licensing strategy makes our technology available to a wide range of companies and research hospitals to boost the efficiency of their various clinical programs,” says SVP of Business Development & Licensing, Dr. Sabine Ott.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="About SIRION Biotech GmbH” data-reactid=”24″>About SIRION Biotech GmbH

SIRION Biotech was founded in 2005 to lead the next generation of viral vector technologies for gene and cell therapy as well as vaccine development. Now SIRION offers one of the world’s most comprehensive viral vector technology platforms based on lenti-, adeno-, and adeno-associated viruses which expedites gene therapy research and advances drug development. SIRION is becoming a partner of choice in this growing sector. LentiBOOST™ has been used in a number of clinical trials from early stage clinical Phase 1/2 through late stage clinical Phase 3 trials and demonstrated clinical success in improving transduction of the therapeutic vector.

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005262/en/” data-reactid=”26″>View source version on businesswire.com: https://www.businesswire.com/news/home/20200407005262/en/

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Contacts” data-reactid=”27″>Contacts

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
lingelbach@sirion-biotech.com” data-reactid=”28″>Corporate Contact
Dieter Lingelbach, COO
SIRION Biotech
+49 89-700-96199-14
lingelbach@sirion-biotech.com

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com” data-reactid=”29″>Media Contact USA
Lisa DeScenza
Vice President, Integrated Communications
LaVoieHealthScience
(978) 395-5970
ldescenza@lavoiehealthscience.com

<p class="canvas-atom canvas-text Mb(1.0em) Mb(0)–sm Mt(0.8em)–sm" type="text" content="Business Development &amp; Licensing Contact
Sabine Ott, Ph.D., SVP Business Development &amp; Licensing
SIRION Biotech
+49 89-700-96199-19
ott@sirion-biotech.com” data-reactid=”30″>Business Development & Licensing Contact
Sabine Ott, Ph.D., SVP Business Development & Licensing
SIRION Biotech
+49 89-700-96199-19
ott@sirion-biotech.com

Let’s block ads! (Why?)


Source link

Load More By admin
Load More In Car

Leave a Reply

Your email address will not be published. Required fields are marked *

Check Also

Don't make social media tech bro billionaires the arbiters of truth – Business Insider – Business Insider

Business Insider It’s hard to believe that in an election year, during a pandemic an…